Catalyst Pharmaceuticals (CPRX) Equity Average (2011 - 2026)

Catalyst Pharmaceuticals (CPRX) has 16 years of Equity Average data on file, last reported at $983.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 29.24% year-over-year to $983.5 million; the trailing twelve-month figure through Mar 2026 stood at $983.5 million (up 29.24% YoY), and the FY2025 full-year result was $841.0 million, up 50.77% from the prior year.
• Equity Average for Q1 2026 stood at $983.5 million, up from $937.3 million in the prior quarter.
• Across five years, Equity Average topped out at $983.5 million in Q1 2026 and bottomed at $213.5 million in Q1 2022.
• The 5-year median for Equity Average is $474.6 million (2024), against an average of $539.4 million.
• The widest annual swing landed in 2022, when Equity Average advanced 22.63%; it then soared 88.55% in 2024.
• A 5-year view of Equity Average shows it stood at $285.2 million in 2022, then advanced by 29.09% to $368.2 million in 2023, then jumped by 88.55% to $694.3 million in 2024, then jumped by 35.0% to $937.3 million in 2025, then advanced by 4.93% to $983.5 million in 2026.
• The last three Equity Average figures came in at $983.5 million (Q1 2026), $937.3 million (Q4 2025), and $888.1 million (Q3 2025), per Business Quant data.

Peer Comparison